We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cambridge Antibody Technology and Philochem Announce Technology Evaluation Agreement
News

Cambridge Antibody Technology and Philochem Announce Technology Evaluation Agreement

Cambridge Antibody Technology and Philochem Announce Technology Evaluation Agreement
News

Cambridge Antibody Technology and Philochem Announce Technology Evaluation Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cambridge Antibody Technology and Philochem Announce Technology Evaluation Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cambridge Antibody Technology (CAT) and Philochem AG announce that they have signed a technology evaluation agreement for Philochem to apply its proprietary DNA-encoded libraries to the discovery of low molecular weight compounds against three undisclosed targets of pharmaceutical interest.

Philochem will use its Encoded Self-Assembling Chemical (ESAC) Libraries, in which chemical pharmacophores (structural features of a molecule that determine its biological activity) are displayed on DNA that contains an associated tag sequence and is selected by binding to protein targets.

Chemical pharmacophores are thereby isolated and identified by their associated DNA tag. This technology is, therefore, analogous to the Phage and Ribosome Display technology used at CAT to develop therapeutic antibodies, in simultaneously selecting the binding molecule and its encoding sequence.

The study will provide CAT with an evaluation of this extension of display technology beyond selection of macromolecules to identification of low molecular weight compounds capable of specific binding to protein targets of pharmaceutical interest, leading to an assessment of its potential to generate leads for small molecule drugs.

The terms of this agreement are not being disclosed.

Advertisement